Log in to search using one of your social media accounts:

 

Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately. On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal came less than a week after Emergent (NYSE: EBS) announced it would buy French pharmaceutical giant Sanofi's sma llpox vaccine business in an all-cash deal worth up to $125 million. "People have been waiting for acquisitions from… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 20, 2017 Category: Biotechnology Authors: Tina Reed Source Type: news

Three-Zone Biosecurity Offers New Hope to Indonesian Farmers
James McGrane, FAO ECTAD Indonesia Team Leader, at his office in Jakarta. Credit: Kanis Dursin/IPSBy Kanis DursinJAKARTA, Indonesia, Jul 10 2017 (IPS)Poultry farmer Bambang Sutrisno Setiawan had long heard about biosecurity but never gave serious thought to it, even when the highly pathogenic avian influenza H5N1 forced him to cull thousands of his layer chickens in 2003 and 2009.Eighteen years into the business, however, Bambang, who is called Ilung by friends, is now converting his second farm into a three-zone biosecurity poultry with a strong conviction that it is the only way to save his business amid continued threat...
Source: IPS Inter Press Service - Health - July 10, 2017 Category: International Medicine & Public Health Authors: Kanis Dursin Tags: Asia-Pacific Economy & Trade Featured Food & Agriculture Headlines Health Projects avian flu biosafety Food and Agriculture Organization of the United Nations (FAO) Improving the lives of rural populations: better nutrition & agricultu Source Type: news

PBL Gains Approval to Advance Next Generation Anthrax Vaccine
Porton Biopharma Ltd (PBL) has announced that it has signed a modification to its contract with the US National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vacci … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 19, 2017 Category: Pharmaceuticals Source Type: news

BioThrax (Anthrax Vaccine Adsorbed Emergent BioSolutions) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2017 Category: Drugs & Pharmacology Source Type: news

Emergent signs $100m BARDA contract to deliver BioThrax
US-based Emergent BioSolutions has signed a $100m contract with the Biomedical Advanced Research and Development Authority (BARDA) to deliver BioThrax (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 21, 2017 Category: Pharmaceuticals Source Type: news

Emergent BioSolutions gets $100 million anthrax contract from feds
Gaithersburg-based Emergent BioSolutions Inc. won another lucrative anthrax contract from the feds, this time totaling $100 million over two years. Emergent (NYSE: EBS) received the contract through the Biomedical Advanced Research and Development Authority to add more of its anthrax vaccine, BioThrax, to the country's national stockpile. The company first announced the planned purchase in December, along with another Centers for Disease Cont rol and Prevention contract worth up to $911 million for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 20, 2017 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

Meet Anne Schuchat, The Pro-Vaccine Researcher Who Just Took Over The CDC
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com.  function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments....
Source: Healthy Living - The Huffington Post - January 24, 2017 Category: Consumer Health News Source Type: news

Porton Biopharma (PBL) Brochure
Porton Biopharma (PBL) manufactures the UK's licensed anthrax vaccine for and on behalf of the UK Government. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 19, 2017 Category: Pharmaceuticals Source Type: news

Our news predictions for 2017
Climate change continues to impact on public health Despite what many commenters have said in 2016, climate change is real and is ongoing. That's the thing about science. Just because you don't believe in it, it doesn't go away. In 2016 we have seen evidence of the impact of climate change in a number of different ways. There was an anthrax outbreak in northern Russia as warm weather caused the release of previously frozen deadly anthrax spores. And many experts think that the spread of the Zika virus across much of the Americas was made possible, in part, by changes in temperature that created environments in which the ...
Source: NHS News Feed - December 30, 2016 Category: Consumer Health News Tags: QA articles Special reports Source Type: news

Why stock in this Gaithersburg biotech is up more than 25 percent
The share price of Gaithersburg-based Emergent BioSolutions Inc. remains up more than 25 percent this week after announcing Dec. 8 it scored federal deals worth up to $1 billion to supply the Strategic National Stockpile for millions of doses of its anthrax vaccine. Emergent (NYSE: EBS) was awarded the contract with the Centers for Disease Control worth up to $911 million for 29.4 million doses of BioThrax through 2021. The company also received a separate notice that the Biomedical Advanced Research… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 13, 2016 Category: American Health Authors: Tina Reed Source Type: news

Why stock in this Gaithersburg biotech is up more than 25 percent
The share price of Gaithersburg-based Emergent BioSolutions Inc. remains up more than 25 percent this week after announcing Dec. 8 it scored federal deals worth up to $1 billion to supply the Strategic National Stockpile for millions of doses of its anthrax vaccine. Emergent (NYSE: EBS) was awarded the contract with the Centers for Disease Control worth up to $911 million for 29.4 million doses of BioThrax through 2021. The company also received a separate notice that the Biomedical Advanced Research… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 13, 2016 Category: Biotechnology Authors: Tina Reed Source Type: news

Warning: Anthrax found at Indiana livestock farm, all animals will be treated with antibiotics and vaccines - is it safe?
(NaturalNews) According to the Indiana Board of Animal Health, anthrax was recently discovered on a southern Indiana beef cattle farm. Following the unexpected and sudden death of a mixed-breed bull, tissue samples collected by a veterinarian revealed that the rod-shaped bacteria  Bacillus anthracis, commonly referred to as anthrax, was at play. Reports indicate that people... (Source: NaturalNews.com)
Source: NaturalNews.com - December 10, 2016 Category: Consumer Health News Source Type: news

HHS supports next-generation anthrax vaccine into advanced development
ASPR's BARDA is contracting with Emergent BioSolutions to work towards licensing an anthrax vaccine with the FDA. (Source: PHPartners.org)
Source: PHPartners.org - September 30, 2016 Category: Global & Universal Source Type: news

Altimmune nabs $120.2 million federal contract for nasal spray anthrax vaccine
Gaithersburg-based Altimmune Inc. was awarded a five-year federal contract worth up to $120.2 million for the development of its nasal spray anthrax vaccine candidate. Under the contract from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, Altimmune was awarded $14.3 million to fund its Phase 1 trial for the vaccine candidate NasoShield. The contract also includes options to receive up to an additional $105.9 million to fund further pr eclinical, clinical and manufacturing… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 10, 2016 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

Altimmune nabs $120.2 million federal contract for nasal spray anthrax vaccine
Gaithersburg-based Altimmune Inc. was awarded a five-year federal contract worth up to $120.2 million for the development of its nasal spray anthrax vaccine candidate. Under the contract from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, Altimmune was awarded $14.3 million to fund its Phase 1 trial for the vaccine candidate NasoShield. The contract also includes options to receive up to an additional $105.9 million to fund further pr eclinical, clinical and manufacturing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 10, 2016 Category: Biotechnology Authors: Tina Reed Source Type: news

Pfenex reports positive Phase Ia Px563L anthrax vaccine study results
US-based, clinical-stage biotechnology company Pfenex has reported a positive outcome from its Phase Ia Px563L anthrax vaccine study. (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2016 Category: Pharmaceuticals Source Type: news

PharmAthene Inc.: Government giving Emergent BioSolutions unfair advantage in anthrax contracting
Annapolis-based biodefense company PharmAthene Inc. filed a complaint against the Department of Health and Human Services, claiming it is giving a de facto sole-source anthrax contract to competitor Emergent BioSolutions Inc. with its latest solicitation. In a protest filed with the U.S. Government Accountability Office, officials from PharmAthene said the solicitation was written in a way that eliminated competition and ensured that an award for a next-generation anthrax vaccine would go to Gaithersburg-based… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 5, 2016 Category: Biotechnology Authors: Tina Reed Source Type: news

PharmAthene Inc.: Government giving Emergent BioSolutions unfair advantage in anthrax contracting
Annapolis-based biodefense company PharmAthene Inc. filed a complaint against the Department of Health and Human Services, claiming it is giving a de facto sole-source anthrax contract to competitor Emergent BioSolutions Inc. with its latest solicitation. In a protest filed with the U.S. Government Accountability Office, officials from PharmAthene said the solicitation was written in a way that eliminated competition and ensured that an award for a next-generation anthrax vaccine would go to Gaithersburg-based… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 5, 2016 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

Siberian Heatwave Sparks Anthrax Outbreak, Killing A Child And Thousands Of Reindeer
At least one child has died in Siberia after an outbreak of naturally occurring anthrax, which has been linked to a decades-old reindeer carcass exposed during a heatwave. Russian officials have said the death of a 12-year-old boy, a member of a reindeer-herding family from the Yamal tundra 1,300 miles north of Moscow, was the first fatality in Siberia linked to the pathogen since 1941. Twenty others have been diagnosed with anthrax, according to CBS. The region’s governor, Dmitry Kobylkin, linked the outbreak to a massive temperature spike in the region that has melted the permafrost ― a thick layer of soil a...
Source: Healthy Living - The Huffington Post - August 2, 2016 Category: Consumer Health News Source Type: news

Anthrax Vaccine Shows Promise in Monkey Trial
FRIDAY, July 1, 2016 -- A vaccine made with a component of the bacteria that causes anthrax protected monkeys from the deadly infection in a preliminary trial. Previous research showed that this component -- the anthrax capsule -- played a pivotal... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 1, 2016 Category: Journals (General) Source Type: news

Anthrax capsule vaccine completely protects monkeys from lethal inhalational anthrax
Vaccination with the anthrax capsule -- a naturally occurring component of the bacterium that causes the disease -- completely protected monkeys from lethal anthrax infection, according to a study. These results indicate that anthrax capsule is a highly effective vaccine component that should be considered for incorporation in future generation anthrax vaccines. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 27, 2016 Category: Science Source Type: news

Anthrax capsule vaccine completely protects monkeys from lethal inhalational anthrax
(US Army Medical Research Institute of Infectious Diseases) Vaccination with the anthrax capsule -- a naturally occurring component of the bacterium that causes the disease -- completely protected monkeys from lethal anthrax infection, according to a study published online this week in the journal VACCINE. These results indicate that anthrax capsule is a highly effective vaccine component that should be considered for incorporation in future generation anthrax vaccines. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 27, 2016 Category: Infectious Diseases Source Type: news

SHOCK FINDING: 30 percent of U.S. military damaged by anthrax vaccine
(NaturalNews) The topic of vaccines tends to inspire strong feelings in people one way or the other, and the admissions made by a CDC whistleblower in the recent documentary VAXXED certainly added fuel to the fire. However, one aspect of the vaccine debate that many people can agree... (Source: NaturalNews.com)
Source: NaturalNews.com - June 14, 2016 Category: Consumer Health News Source Type: news

Nigeria: Anthrax - Kaduna Procures 150,000 Doses of Vaccines
[Daily Trust] Kaduna -Kaduna State Commissioner for Agriculture and Forestry, Dr. Manzo Maigari has said that there is no case of anthrax in the state,saying 150,000 doses of vaccines have been procured as a preventive measure. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 3, 2016 Category: African Health Source Type: news

Development of a Solid Dose Injection Recombinant Anthrax Vaccine
Glide Technologies is a UK development company focused on solid dose formulations of therapeutics and vaccines, and non-invasive diagnostics. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2016 Category: Pharmaceuticals Source Type: news

Solid Formulation of a Recombinant Anthrax Vaccine
Pfenex and Glide Pharma have an ongoing collaboration to develop an anthrax vaccine containing the recombinant protective antigen (rPA) from Bacillus anthracis produced using Pfēnex expression technology, which is suitable for delivery with the Glide… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2016 Category: Pharmaceuticals Source Type: news

FDA uses 'animal' rule to approve anthrax vaccine for humans ... You're just an experimental animal to the vaccine industry
(NaturalNews) The FDA has dramatically expanded the permitted uses of the anthrax vaccine using a post-9/11 law known as the Bioterrorism Act of 2002. A clause of that act, known as the Animal Rule, allows the FDA to bypass human studies of drugs in cases where exposing humans to... (Source: NaturalNews.com)
Source: NaturalNews.com - December 8, 2015 Category: Consumer Health News Source Type: news

FDA Expands Use of Anthrax Vaccine to Include Postexposure Prevention (FREE)
By Kristin J. Kelley Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The only FDA-licensed anthrax vaccine, marketed as BioThrax, is … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 25, 2015 Category: Primary Care Source Type: news

Anthrax Vaccine Approved for Postexposure ProtectionAnthrax Vaccine Approved for Postexposure Protection
Studies indicate that people receiving BioThrax after a confirmed or suspected exposure to the bacterium that causes the disease may have a 70% chance of surviving. FDA Approvals (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - November 24, 2015 Category: Emergency Medicine Tags: Infectious Diseases News Alert Source Type: news

Anthrax Vaccine Approval Expanded
Now sanctioned for adults 18 to 65 with known or suspected exposure Source: HealthDay Related MedlinePlus Page: Anthrax (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 24, 2015 Category: Consumer Health News Source Type: news

FDA approves expanded use of Emergent BioSolution's anthrax vaccine
(Reuters) - The U.S. Food and Drug Administration approved to expand the use of Emergent BioSolutions Inc's anthrax vaccine to prevent suspected or confirmed exposure to the bacterium that causes the disease. (Source: Reuters: Health)
Source: Reuters: Health - November 23, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves vaccine for use after known or suspected anthrax exposure
The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine’s new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 23, 2015 Category: American Health Source Type: news

Development of New Anthrax Vaccine Underway With HHS Support
A new anthrax vaccine that could be easier and faster to produce than the existing licensed product will undergo initial clinical studies through an agreement between the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) and Pfenex, Inc. of San Diego. (Source: PHPartners.org)
Source: PHPartners.org - November 9, 2015 Category: Global & Universal Source Type: news

FDA and access to medical countermeasures during public health emergencies
By: Brooke Courtney, J.D., M.P.H. Just weeks after witnessing the fall of the World Trade Center on Sept. 11, 2001, I was a student volunteer in a New York City hospital emergency department when several people arrived saying they had been exposed to anthrax. One had even brought a small plastic bag holding white powder. Around this time, the media was reporting on letters mailed that were laced with white powder confirmed to be Bacillus anthracis, which causes anthrax. At the hospital, we wondered whether we might become exposed to anthrax and how it could be prevented or treated. We quickly escorted the patients who had ...
Source: Mass Device - October 13, 2015 Category: Medical Equipment Authors: MassDevice Tags: Blog FDA Source Type: news

Development of New Anthrax Vaccine Underway With HHS Support
A new anthrax vaccine that could be easier and faster to produce than the existing licensed product will undergo initial clinical studies through an agreement between the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) and Pfenex, Inc. of San Diego. (Source: PHPartners.org)
Source: PHPartners.org - August 27, 2015 Category: Global & Universal Source Type: news

Pfenex receives $143.5m contract to develop new anthrax vaccine
US-based Pfenex has received a $143.5m five-year contract from the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS) to advance development of Px563L, a mutant recombinant protective a… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 18, 2015 Category: Pharmaceuticals Source Type: news

Immunovaccine and PharmAthene to develop new anthrax vaccine
Immunovaccine and PharmAthene have signed an exclusive worldwide licence agreement to develop and commercialise recombinant protective antigen anthrax vaccine (rPA) candidate. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 9, 2015 Category: Pharmaceuticals Source Type: news

Angola: Over 100,000 Cattle Await Vaccine
[ANGOP] Sumbe -At least 126,800 head of cattle will be vaccinated in central Cuanza Sul province under an anthrax immunisation drive between July and September this year. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 1, 2015 Category: African Health Source Type: news

The End of Ebola? Lessons at the Epidemic's One Year Anniversary
"That's the anthrax building," a colleague told me several years ago, pointing to a squat reddish-brown brick building in the middle of Fort Detrick, for many years the U.S. Army's center for biological warfare research. Cinderblocks now sealed up all of the doors and windows. Inside, anthrax -- a deadly pathogen -- still lurks. Outside, we are generally spared. For years, the U.S. had developed stores of anthrax spores as biological warfare, but destroyed these in 1969. Yet after 9/11, someone sent letters containing the pathogen to various journalists and senators. Many observers feel that the culprit remains ...
Source: Healthy Living - The Huffington Post - March 30, 2015 Category: Consumer Health News Source Type: news

The End of Ebola? Lessons at the Epidemic's One Year Anniversary
"That's the anthrax building," a colleague told me several years ago, pointing to a squat reddish-brown brick building in the middle of Fort Detrick, for many years the U.S. Army's center for biological warfare research. Cinderblocks now sealed up all of the doors and windows. Inside, anthrax -- a deadly pathogen -- still lurks. Outside, we are generally spared. For years, the U.S. had developed stores of anthrax spores as biological warfare, but destroyed these in 1969. Yet after 9/11, someone sent letters containing the pathogen to various journalists and senators. Many observers feel that the culprit remains ...
Source: Science - The Huffington Post - March 30, 2015 Category: Science Source Type: news

HHS Seeks to Develop Improved Anthrax Vaccine
Advanced development is underway on an improved anthrax vaccine that could provide protection in fewer doses than the currently licensed anthrax vaccine and so may be more cost-effective to stockpile. (Source: PHPartners.org)
Source: PHPartners.org - March 24, 2015 Category: Global & Universal Source Type: news

U.S. funding research of better anthrax vaccine: health officials
(Reuters) - Government-funded clinical trials are under way of an improved anthrax vaccine requiring fewer doses and that has the potential to boost immunity faster, top health officials said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - March 23, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Donna Altenpohl on Ebola
Ebola response is a model of collaboration The constant stream of photos and reports about Ebola from West Africa tragically illustrate the speed at which disease can spread, devastating communities and reshaping daily life. GSK is working with many partners at an unprecedented speed and with passionate focus to try to develop a vaccine to limit the total number of deaths from this epidemic and future outbreaks. While the current crisis is our focus, there also are lessons for the future: US health and security can be threatened by events half a world away and the global community is not fully prepared for such disease out...
Source: PHRMA - October 30, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news

Vaccine for Ebola? Experts answer questions
To learn more about this outbreak and the creation of new human vaccines, infectious disease experts who have led vaccine studies for such global pathogens as cholera, West Nile virus, dengue, typhoid fever and anthrax speak to reporters and answer questions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 29, 2014 Category: Science Source Type: news

$14.5 million grant awarded to continue anthrax studies
(Oklahoma Medical Research Foundation) The National Institutes of Health has awarded the Oklahoma Medical Research Foundation a five-year, $14.5 million grant to continue its research on anthrax and the bacteria's effects on humans. Studies will focus on three areas: parts of the anthrax bacteria that cause inflammation and human pathology of the disease, the anthrax vaccine that is administered to US military personnel, and testing human components that contribute to inflammation accompanying bacterial infections. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 20, 2014 Category: Global & Universal Source Type: news

Specialty Vaccine Company PaxVax Expands Global Commercial Team
REDWOOD CITY, Calif.--(Healthcare Sales & Marketing Network)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the expansion of its global commercial team with the appointments of Jonathan Klock as Vice President ... Biopharmaceuticals, PersonnelPaxVax, vaccine, Vivotif, typhoid, cholera, anthrax (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 7, 2014 Category: Pharmaceuticals Source Type: news

Op-Ed Contributor: Anthrax? That’s Not the Real Worry
Labs are working with virulent flu strains that could start a pandemic. (Source: NYT Health)
Source: NYT Health - June 29, 2014 Category: Consumer Health News Authors: By MARC LIPSITCH Tags: Viruses Epidemics Influenza Research Vaccination and Immunization Source Type: news

Michigan Army National Guard Vaccination Initiative: Health Alert for CliniciansMichigan Army National Guard Vaccination Initiative: Health Alert for Clinicians
The Michigan Army National Guard has initiated a statewide smallpox and anthrax vaccination initiative for approximately 1,000 National Guard personnel. State Health Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2014 Category: Consumer Health News Tags: News Source Type: news

Here’s What You Need to Know About the Anthrax Accident
The Centers for Disease Control and Prevention announced on Thursday that 86 of its staff members in Atlanta are being monitored for possible anthrax exposure. Scientists at the facility routinely study the bioterror agent, which is classified at “Biosafety Level 3,” meaning it can cause fatal infections and is transmitted easily by inhalation. Bacillus anthracis occurs naturally in soil and can infect wild and domestic animals, who can transmit the bacteria to humans. In the U.S., livestock are routinely vaccinated against anthrax, which keeps the number of domestic outbreaks low. Once inside the body, anthrax...
Source: TIME.com: Top Science and Health Stories - June 20, 2014 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized anthrax CDC Source Type: news

10 year study shows 'Lethal Factor' could be X-factor for new anthrax vaccine
A section of the anthrax toxin Lethal Factor that could help produce a more effective vaccine, researchers report. Anthrax is a potentially lethal disease caused by a bacterium. The bacteria produce spores that when inhaled, ingested or absorbed into the skin release toxins. When anthrax affects the lungs or intestines it can cause death within a few days. Infection can occur from contact with infected livestock, meat or hides, but most people know about anthrax from its use as a biological weapon, notably in the 2001 attacks through the US postal system. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 1, 2014 Category: Science Source Type: news